Geert Cauwenbergh, President & CEO at RXi Pharmaceuticals Corp (RXII), bought 10,000 shares at $0.69 ($7K) on 2017-02-17, disclosed to the SEC on 2017-02-21.
Open-market purchase of $7k RXII by President & CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.69 | 200 | $138 | 2.0% |
| 2 | $0.69 | 6,883 | $5K | 68.5% |
| 3 | $0.70 | 2,917 | $2K | 29.5% |
| Total | $0.69 avg | 10,000 | $7K | 100% |
| Filing → |
| RXII | BUY | 2017-06-22 | $6K | — | Filing → |
| RXII | BUY | 2017-04-26 | $7K | — | Filing → |
| RXII | BUY | 2017-03-20 | $8K | — | Filing → |